[Federal Register Volume 59, Number 2 (Tuesday, January 4, 1994)]
[Notices]
[Page 308]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 94-39]
[[Page Unknown]]
[Federal Register: January 4, 1994]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
MEDWATCH Conference on Drug and Device-induced Disease:
Developing a Blueprint for the Future; Notice of Public Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
Commissioner's MEDWATCH Conference on Drug and Device-Induced Disease:
Developing a Blueprint for the Future. The conference is co-sponsored
by FDA and the American Medical Association (AMA) in cooperation with
the following organizations: American Association of Colleges of
Nursing, American Association of Colleges of Pharmacy, American
Association of Dental Schools, American Dental Association, American
Hospital Association, American Nursing Association, American Society of
Clinical Pharmacology and Therapeutics, American Society of Hospital
Pharmacists, Association of American Medical Colleges, and the Council
on Education in Clinical Pharmacology and Therapeutics.
DATES: The conference will be held on January 21, 1994, from 8:30 a.m.
to 5 p.m., and January 22, 1994, from 8:30 a.m. to 12:30 p.m.
ADDRESSES: The conference will be held at the Stouffer Mayflower Hotel,
1127 Connecticut Ave. NW., Washington, DC 20036. Registration is
required.
FOR FURTHER INFORMATION CONTACT: Mary Pat Couig, Office of Health
Affairs (HFY-40), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-443-5470. For registration call the American
Medical Association at 1-800-621-8335.
SUPPLEMENTARY INFORMATION: Drug and device-induced diseases are serious
health problems. It is estimated that 2 to 10 percent of all
hospitalizations are a result of serious adverse events. The purpose of
this conference is to develop recommendations on ways to heighten
health professionals' awareness of the extent and spectrum of drug and
device-induced disease and to break down barriers to the discovery and
reporting of important adverse events to FDA and manufacturers by: (1)
Strengthening undergraduate curricula, (2) enhancing postgraduate
training, and (3) building user-friendly reporting mechanisms for
health professionals.
David A. Kessler, Commissioner of Food and Drugs, and James S.
Todd, Executive Vice President of the AMA, will be the keynote
speakers.
The conference should be of interest to the following groups:
Practicing health professionals, health professional organizations,
health professions educators (undergraduate and graduate), health
professionals of State health departments, regulatory and safety
surveillance professionals, and hospital personnel (e.g, risk managers/
quality assurance personnel and members of Pharmacy and Therapeutics
Committees).
This is a participatory conference. Recommendations from the
breakout sessions will be presented on the second day of the conference
and their implementation discussed at the final panel discussion.
Dated: December 23, 1993.
David A. Kessler,
Commissioner of Food and Drugs.
[FR Doc. 94-39 Filed 1-3-94; 8:45 am]
BILLING CODE 4160-01-F